Chromatographic Fingerprinting

Thermosensitive liposomes (TSLs) have emerged as a novel and adaptable platform in nanomedicine, enabling targeted and strategic drug delivery through their thermoresponsive release characteristics. Designed to remain stable at physiological temperatures and to undergo phase transitions at severe hyperthermia (41–43 °C), TSLs can release encapsulated therapeutic agents (e.g., doxorubicin, mitoxantrone, oxaliplatin) in controlled spatial and temporal concentrations to targeted tumors. Preclinical trials demonstrate that TSLs, particularly when combined with localized hyperthermia therapies such as focused ultrasound or radiofrequency heating, significantly enhance intratumoral drug delivery, improve therapeutic efficacy, and diminish systemic toxicity compared to standard chemotherapy. Strategic design changes, including adding lysolipids to lower phase transition temperatures and PEGylation to improve circulation and stem stability, can further improve pharmacokinetics and biocompatibility. A combination of real-time imaging measures gives us a greater chance to follow the liposomes' movement and release medications, which lets us tailor the therapy program to fit each patient. Even though these are good steps forward, there are still problems with standardizing formulations, keeping the temperature very stable throughout hyperthermia, and making preclinical research work for a lot of people in the clinic. Still, ongoing research that focuses on improving the formulation and combining it with other innovative treatments like immunotherapy, gene therapy, and non-invasive thermal procedures is essential to realize the full clinical potential of TSLs. In short, TSLs are a very promising idea for a safe and effective cancer treatment that can be targeted. They also make it possible to improve therapeutic results while keeping off-target side effects to a minimum